

Leamon Christopher P
Form 4
December 19, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Leamon Christopher P

(Last) (First) (Middle)

3000 KENT AVE, SUITE A1-100

(Street)

WEST LAFAYETTE, IN 47906

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDOCYTE INC [ECYT]

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Vice President of Research

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V | Amount or Price (A) or (D) | | |
| Common Stock | 12/17/2018 | | M | | 20,000 A \$ 2.54 | 142,482 ⁽¹⁾ | D |
| Common Stock | 12/17/2018 | | M | | 26,177 A \$ 3.82 | 168,659 | D |
| Common Stock | 12/17/2018 | | M | | 13,089 A \$ 7.49 | 181,748 | D |
| Common Stock | 12/17/2018 | | M | | 22,500 A \$ 9.05 | 204,248 | D |
| Common Stock | 12/17/2018 | | M | | 20,004 A \$ 3.55 | 224,252 | D |

Edgar Filing: Leamon Christopher P - Form 4

| | | | | | | | |
|--------------|------------|---|---|---|---------|---------|---|
| Common Stock | 12/17/2018 | M | 2 | A | \$ 5.1 | 224,254 | D |
| Common Stock | 12/17/2018 | M | 2 | A | \$ 3.18 | 224,256 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (right to buy) | \$ 2.54 | 12/17/2018 | | M | 20,000 | <u>(2)</u> 03/05/2019 | Common Stock | 20,000 |
| Stock Option (right to buy) | \$ 3.82 | 12/17/2018 | | M | 26,177 | <u>(2)</u> 02/11/2020 | Common Stock | 26,177 |
| Stock option (right to buy) | \$ 7.49 | 12/17/2018 | | M | 13,089 | <u>(2)</u> 03/11/2021 | Common Stock | 13,089 |
| Stock Option (right to buy) | \$ 9.05 | 12/17/2018 | | M | 22,500 | <u>(2)</u> 04/14/2021 | Common Stock | 22,500 |
| Stock option (right to buy) | \$ 3.55 | 12/17/2018 | | M | 20,004 | <u>(2)</u> 02/28/2022 | Common Stock | 20,004 |
| Stock option | \$ 5.1 | 12/17/2018 | | M | 2 | <u>(2)</u> 02/04/2025 | Common Stock | 2 |

(right to buy)

| | | | | | | | | |
|-----------------------------|---------|------------|---|---|-----|------------|--------------|---|
| Stock option (right to buy) | \$ 3.18 | 12/17/2018 | M | 2 | (3) | 02/04/2026 | Common Stock | 2 |
|-----------------------------|---------|------------|---|---|-----|------------|--------------|---|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|----------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Leamon Christopher P 3000 KENT AVE, SUITE A1-100 WEST LAFAYETTE, IN 47906 | | | Vice President of Research | |

Signatures

/s/ Michael A. Sherman, Attorney-in-Fact for Christopher P. Leamon (power of attorney previously filed) 12/19/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 263 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018.
- (2) The option is fully vested and immediately exercisable.
- (3) Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.